Jared Kelly - 01 Jan 2026 Form 3 Insider Report for ONCOLYTICS BIOTECH INC (ONCY)

Role: Chief Executive Officer, Director
Signature: /s/ Kirk Look, Attorney-in-Fact
Issuer symbol: ONCY
Transactions as of: 01 Jan 2026
Net transactions value: $0
Form type: 3
Filing time: 02 Jan 2026, 16:30:39 UTC
Next filing: 13 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kelly Jared	Chief Executive Officer, Director	C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO	/s/ Kirk Look, Attorney-in-Fact	02 Jan 2026	0002103581

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ONCY	Common Shares						73,900	01 Jan 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ONCY	Stock Option							01 Jan 2026	Common Shares	2,850,000	$0.5700	Direct	F1, F2
holding	ONCY	Stock Option							01 Jan 2026	Common Shares	450,000	$1.08	Direct	F3
holding	ONCY	Stock Option							01 Jan 2026	Common Shares	350,000	$0.9900	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests in three equal annual installments beginning on June 11, 2026.
F2	The exercise price is listed in Canadian dollars.
F3	The stock option vests in three equal annual installments beginning on August 15, 2026.
F4	The stock option vests in three equal annual installments beginning on December 15, 2026.

Remarks:

Exhibit 24 - Power of Attorney.